IP Library Granted Patent US 8,383,392
Granted Patent B2
US 8,383,392 · App. 12/678,101 · Granted Feb 26, 2013

Transformant and method for production of non-natural antibiotic

Inventors: Naomi Sumida (Odawara, JP); Manabu Watanabe (Odawara, JP); Koji Yanai (Odawara, JP)
Assignee: Meiji Seika Pharma Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,392
App. No.
12/678,101
Granted
Feb 26, 2013
Kind
B2
Abstract

Disclosed is a transformant prepared by introducing a ketoreductase gene involved in the biosynthesis of L-epivancosamine into an actinobacterium originally capable of producing daunorubicin. Also disclosed is a process of efficiently producing a non-natural daunorubicin derivative using the transformant. The transformant is capable of efficiently producing a non-natural daunorubicin derivative such as epidaunorubicin.

Claims (10)

1. A transformant of an actinobacterium, originally capable of producing daunorubicin, comprising a ketoreductase gene involved in the biosynthesis of L-epivancosamine, wherein the ketoreductase gene is selected from:

a) a gene which encodes a protein comprising the amino acid sequence of SEQ ID NO: 1;

b) a gene which encodes a protein comprising an amino acid sequence in which 1-20 amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 1 wherein said amino acid sequence has ketoreductase activity;

c) a gene which encodes a protein comprising an amino acid sequence having a 95% or more identity with the amino acid sequence of SEQ ID NO: 1 wherein said amino acid sequence has ketoreductase activity; or

d) a DNA consisting of the nucleotide sequence of SEQ ID NO: 2.

2. The transformant according to claim 1 , which produces epidaunorubicin as the derivative of daunorubicin.

3. The transformant according to claim 1 , wherein the host actinobacterium is Streptomyces coeruleorubidus.

4. A process of producing a derivative of daunorubicin, comprising the steps of:

cultivating the transformant of claim 1 , and

collecting epidaunorubicin as the derivative of daunorubicin from the resulting culture broth.

Assignments (2)
CHANGE OF NAME Recorded Jan 8, 2013
From: MEIJI SEIKA KAISHA, LTD.
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 029586/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2010
From: SUMIDA, NAOMI; WATANABE, MANABU; YANAI, KOJI
To: MEIJI SEIKA KAISHA, LTD.
Reel/Frame 024193/0561 →
Priority Claims (1)
JP 2007-239001 · Sep 14, 2007 · national
Continuity (1)
Related Publication 20100255543A1 · Oct 7, 2010